Background: Patients (pts) with ROS1+ advanced NSCLC can be effectively treated with ROS1 tyrosine kinase inhibitors (TKIs). However, acquired resistance inevitably develops, resulting in disease relapse. Repotrectinib is a potent next-generation ROS1/TRK/ALK TKI, which inhibits ROS1 with a >90-fold greater potency (IC 50 <0.2 nM) than crizotinib. Preclinical studies demonstrate robust activity of repotrectinib against all known clinical ROS1 resistance mutations, including ROS1 G2032R resistance solvent-front mutation. Method: In this phase I study (NCT03093116), eligible adult pts with TKI-naïve or -pretreated advanced ALK/ROS1/TRK+ solid tumors received repotrectinib. Asymptomatic brain metastases were allowed. Primary objectives were to determine the MTD and RP2D of repotrectinib. Secondary objectives were to assess the safety, pharmacokinetics, and preliminary anti-tumor efficacy. This is a subgroup analysis of the ROS1+ NSCLC pts enrolled in the study. Results: As of July 13, 2018, 30 pts with advanced ROS1+ NSCLC have been treated at 5 dose levels, ranging from 40 to 240 mg/day and 160 mg twice a day; 10 were TKInaïve pts; 20 were TKI-refractory pts; and 16 had baseline CNS metastases. Based on Blinded Independent Central Review (BICR), 27 ROS1+ NSCLC pts were evaluable (10 TKI-naïve and 17 TKI-pretreated) and anti-tumor activity was observed at all dose levels. The confirmed objective response rate (ORR) was 80% in TKI-naïve pts, 18% in all TKI-pretreated pts, and 23% in patients with 1 prior TKI treatment. The intracranial confirmed ORR was 100% and 25% for TKI-naïve and TKI-pretreated pts, respectively. Tumor regressions were observed in 4 crizotinib-pretreated patients with a ROS1 G2032R solvent front resistance mutation, with 1 confirmed PR having a duration of response of 7.4 months dosed at 160 mg QD. A total of 72 pts has been treated in the ongoing TRIDENT-1 Phase 1 study and comprise the safety analysis group. Common (>10% of pts) treatment-related AEs included dizziness (50%), dysgeusia (46%), paresthesia (29%), constipation (19%), fatigue (18%), anemia (12.5 %) and nausea (11%). 4 DLTs were observed including 2 Grade 3 and 1 Grade 2 dizziness (at doses 240 mg QD and above) and 1 Grade 3 case of dyspnea and hypoxia. The MTD has not yet been reached. Conclusion: Repotrectinib is well tolerated and demonstrates promising activity in pts with advanced ROS1+ NSCLC, including those who failed prior TKI(s) or have tumors with solvent-front ROS1 resistance mutations. These phase 1 data warrant further clinical testing of repotrectinib in ROS1+ NSCLC. Keywords: G2032R, Mutation, resistance, ROS1 2 Q3W until disease progression or unacceptable toxicity. The results mirrored previous findings in the similar CheckMate 017/057 studies, which included few Asian patients. PROs in CheckMate 017/057 showed reductions in disease-related symptom burden and improvement in health-related quality of life (HRQOL). This study investigated whether similar improvements occurred in CheckMate 078. Method: Symptom burden was assessed using the Lung Cancer Symptom Scale (LCSS) average symptom burden index (ASBI). HRQOL was assessed using the LCSS 3-item global index (3-IGI) and EQ-5D-3L utility index (UI) and visual analog scale (VAS). Assessments for nivolumab and docetaxel occurred at baseline and every 4 and 3 weeks, respectively, up to week 24, and thereafter every 6 weeks for both treatments. Results: Of 504 randomized patients, 458 (91%) had evaluable PROs with baseline assessment and !1 post-baseline assessment (90.4% were Asian and 60.0% had non-squamous tumor histology). Compliance was !83% for all on-treatment PRO assessments. Ten or more patients remained on nivolumab and docetaxel until week 72 and 30, respectively. Time to first deterioration (TTD) was significantly prolonged with nivolumab vs docetaxel for all PRO measures; hazard ratios (95% confidence interval) were 0.47 (0.35À0.64) for LCSS-ASBI, 0.62 (0.47À0.83) for LCSS-3-IGI, and 0.56 (0.44À0.71) for both EQ-5D-3L VAS and UI. Deterioration rates at week 12 were significantly lower with nivolumab (LCSS, n¼313; EQ-5D-3L, n¼312) than docetaxel (LCSS, n¼137; EQ-5D-3L, n¼142) for LCSS-ASBI (31.6% vs 46.7%), EQ-5D-3L VAS (46.8% vs 58.5%), and EQ-5D-3L UI (36.5% vs 51.4%). Patients treated with nivolumab demonstrated clinically meaningful improvements for most LCSS-ASBI assessments after week 30 and all LCSS-3-IGI assessments after week 16; no clinically meaningful improvements were observed with docetaxel (descriptive). HRQOL improvements with nivolumab were observed with the EQ-5D-3L UI (weeks 20À72) and VAS (weeks 16À54), but most were not clinically meaningful. Conclusion: HRQOL and symptom burden improved with nivolumab vs docetaxel in CheckMate 078. Deterioration rates up to week 12 decreased and TTD was delayed with nivolumab vs docetaxel. Patients treated with nivolumab showed clinically meaningful improvement in symptom burden from baseline. These findings are consistent with those from CheckMate 017/057. Keywords: Advanced NSCLC, Nivolumab, Docetaxel, Patient-Reported Outcomes 
